Conrad Fischer says andexanet was withdrawn from the market because it caused clotting, a pointed safety signal for clinicians relying on reversal agents.
Andexanet for reversing factor Xa (ten a) inhibitors has been WITHDRAWN from the market.
It led to CLOTTING
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new expert voices, debates, and emerging ideas.
← Back to Healthcare